Century Therapeutics Updates on Cell Therapy Advancements

An update from Century Therapeutics ( (IPSC) ) is now available.

On December 12, 2025, Century Therapeutics updated its slide presentation to reflect advancements in its cell therapy pipeline, which will be used in investor meetings. The company is progressing with its Allo-Evasion technology, with key programs like CNTY-101 in Phase 1/2 trials for autoimmune diseases and CNTY-813 in preclinical development for Type 1 Diabetes. The announcement highlights the company’s strategic focus on executing high-impact programs and extending its cash runway beyond key clinical milestones anticipated in late 2027.

The most recent analyst rating on (IPSC) stock is a Hold with a $0.56 price target. To see the full list of analyst forecasts on Century Therapeutics stock, see the IPSC Stock Forecast page.

Spark’s Take on IPSC Stock

According to Spark, TipRanks’ AI Analyst, IPSC is a Neutral.

Century Therapeutics’ overall stock score is primarily influenced by its financial performance, which shows strong revenue growth but ongoing operational losses. The technical analysis indicates a positive short-term trend, while the valuation remains challenging due to negative earnings. The recent corporate event of expanding the Board is a positive strategic move, enhancing the company’s potential for future growth.

To see Spark’s full report on IPSC stock, click here.

More about Century Therapeutics

Century Therapeutics operates in the biotechnology industry, focusing on the development of transformative cell therapies. The company specializes in immune evasion engineering and is advancing its pipeline of induced pluripotent stem cell (iPSC) derived therapies, targeting autoimmune diseases and cancer.

Average Trading Volume: 1,000,748

Technical Sentiment Signal: Sell

Current Market Cap: $51.71M

Find detailed analytics on IPSC stock on TipRanks’ Stock Analysis page.